Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 8/20 | 0.49 |
| ▸ | CA2 | P00918 | 8/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17364289 | 0.92 | MEN1 (0.49) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL13996639 | 0.91 | MEN1 (0.50) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL15445093 | 0.90 | MEN1 (0.49) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL29679063 | 0.87 | MEN1 (0.44) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL9971647 | 0.87 | MEN1 (0.44) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL13077420 | 0.87 | MEN1 (0.44) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL3486898 | 0.87 | MEN1 (0.44) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL22940247 | 0.86 | TDP1 (0.61) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL27376565 | 0.84 | TDP1 (0.58) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL18179121 | 0.84 | MEN1 (0.42) | TDP1MEN1KMT2AGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981043-B2 | Analgesic conjugates | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20150374836-A1 | ANALGESIC CONJUGATES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374836-A1 | ANALGESIC CONJUGATES | OPRL1, OPRK1, GRM5 | TDP1 4354/4885MEN1 4401/4885KMT2A 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.